The abstract is read at the publisher; the summary is JClub's.
In the RIVET trial of 30-day rifamycin SV MMX in compensated cirrhosis patients, rifamycin did not significantly enrich gut antimicrobial resistance genes versus placebo after FDR adjustment.
- Why it matters: ARG carriage in liver cirrhosis is linked to worse outcomes and may be amplified by repeated antibiotic exposure and hospitalizations, but rifamycin MMX effects on the gut resistome were unknown.
- What they did: In a randomized, double-blind, placebo-controlled study (15 rifamycin SV MMX, 15 placebo), shotgun metagenomic sequencing was performed before and after 30 days, with ARGs annotated using the Comprehensive Antibiotic Resistance Database and analyzed by LEfSe, paired-Wilcoxon, MaAsLin3, and machine learning.
- The result: Complementary analyses showed a trend toward lower vancomycin resistance ARGs (including vanW and vanT operon-associated genes) after rifamycin exposure, while Enterobacteriaceae-associated efflux regulators rose nominally but did not survive FDR; no infection or treatment-related safety concerns emerged.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.